SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) shares were down 20% during trading on Tuesday . The company traded as low as C$4.65 and last traded at C$4.65. Approximately 1,827 shares were traded during trading, a decline of 23% from the average daily volume of 2,364 shares. The stock had previously closed at C$5.81.
SanBio Trading Down 20.0 %
The stock has a fifty day moving average of C$4.40 and a 200 day moving average of C$4.04.
About SanBio
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
See Also
- Five stocks we like better than SanBio
- Basic Materials Stocks Investing
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
- About the Markup Calculator
- 3 Stocks With Rising Prices That Are Likely to Split in 2025
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Why Adobe Stock Could Be the Best Dip Buy in Tech Right Now
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
